We observed that VSTM2A significantly enhances immune activation by releasing significant granzyme B and IFN-γ cytokines, supporting VSTM2A as a promising agent in the fight against CRC by interrupting the PD-L1/PD-1 axis. This evidence concerns the gene PDCD1 and colorectal carcinoma.